Fidelity Investments
ALXO icon

Fidelity Investments’s ALX Oncology ALXO Stock Holding History

Fidelity Investments’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.4K Buy
13,242
+256
+2% +$458 ﹤0.01% 4554
2026
Q1 		$26K Hold
12,986
– – ﹤0.01% 4413
2025
Q4 		$14.7K Hold
12,986
– – ﹤0.01% 4600
2025
Q3 		$23.8K Sell
12,986
-5,047
-28% -$4.37K ﹤0.01% 4288
2025
Q2 		$7.49K Sell
18,033
-3,955
-18% -$2K ﹤0.01% 4611
2025
Q1 		$13.7K Sell
21,988
-1,829,568
-99% -$2.2M ﹤0.01% 4374
2024
Q4 		$3.09M Sell
1,851,556
-4,013,550
-68% -$6.17M ﹤0.01% 2312
2024
Q3 		$10.7M Sell
5,865,106
-1,949,890
-25% -$7.25M ﹤0.01% 1898
2024
Q2 		$47.1M Buy
7,814,996
+292,184
+4% +$3.59M ﹤0.01% 1334
2024
Q1 		$83.9M Buy
7,522,812
+49,991
+0.7% +$702K 0.01% 1131
2023
Q4 		$111M Buy
7,472,821
+1,880,874
+34% +$17.8M 0.01% 968
2023
Q3 		$26.8M Sell
5,591,947
-538,592
-9% -$2.92M ﹤0.01% 1473
2023
Q2 		$46M Buy
6,130,539
+1,098
+0% +$7.19K ﹤0.01% 1310
2023
Q1 		$27.7M Buy
6,129,441
+16,013
+0.3% +$121K ﹤0.01% 1484
2022
Q4 		$68.9M Buy
6,113,428
+1,482,854
+32% +$16.7M 0.01% 1118
2022
Q3 		$44.3M Buy
4,630,574
+644,360
+16% +$7.51M ﹤0.01% 1290
2022
Q2 		$32.2M Buy
3,986,214
+427,260
+12% +$4.65M ﹤0.01% 1448
2022
Q1 		$60.1M Buy
3,558,954
+966,015
+37% +$16.5M ﹤0.01% 1318
2021
Q4 		$55.7M Buy
2,592,939
+1,333,523
+106% +$57.5M ﹤0.01% 1379
2021
Q3 		$93M Sell
1,259,416
-4,557
-0.4% -$304K 0.01% 1132
2021
Q2 		$69.1M Buy
1,263,973
+14,465
+1% +$866K 0.01% 1289
2021
Q1 		$92.1M Buy
1,249,508
+181,009
+17% +$14.2M 0.01% 1102
2020
Q4 		$92.1M Buy
1,068,499
+319,669
+43% +$19.2M 0.01% 1072
2020
Q3 		$28.3M Buy
+748,830
New +$29.4M ﹤0.01% 1427

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Fidelity Investments's ALXO Position: Q2 2026 in Review

Fidelity Investments increased its ALX Oncology (ALXO) stake by 2% in Q2 2026, buying an estimated $458 and bringing the position to 13,242 shares worth $27.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4554.

Fidelity Investments first reported a position in ALXO in Q3 2020 and has held it in 24 quarters since. The position peaked at $111M in Q4 2023. 93 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

  • Fidelity Investments held 13,242 shares of ALX Oncology worth $27.4K as of Q2 2026.
  • Fidelity Investments bought 256 ALX Oncology shares in Q2 2026, an estimated $458.
  • ALX Oncology made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #4554 holding.
  • Fidelity Investments first reported a position in ALX Oncology in Q3 2020 and has held it in 24 quarters since.
  • Fidelity Investments's ALX Oncology position peaked at $111M in Q4 2023.
  • 93 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.